At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
Akt Inhibitor MK2206drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
In Brief
A Phase 2 clinical trial evaluating Akt Inhibitor MK2206 for Adenocarcinoma of the Gastroesophageal Junction and 4 related conditions. Completed, enrolled 75 participants across 187 sites in 2 countries.
Detailed Summary
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with advanced gastric or gastroesophageal junction cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma, Recurrent Gastric Carcinoma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartJan 2011
Primary CompletionMay 2014
Study CompletionJul 2015
TodayJul 2026
First PostedDec 15, 2010
Enrollment StartJan 1, 2011
Primary CompletionMay 1, 2014
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.5 years ago
Interventions
Akt Inhibitor MK2206drug
Given PO